-
PD0325901: MEK Inhibition Meets Genome Folding
2026-09-20
A translational strategy for using PD0325901 to connect pathway engagement, cancer-cell phenotypes, xenograft evidence, and emerging principles of genome organization without overstating cross-domain biology.
-
AY 9944 Dihydrochloride: DHCR7 Research Guide
2026-09-19
AY 9944 dihydrochloride is a selective DHCR7 inhibitor that drives 7-dehydrocholesterol accumulation by blocking its conversion to cholesterol. Product data report a 13 nM IC50 against recombinant human DHCR7, while 2026 genetic evidence links dhcr7 disruption to stronger antiviral resistance in grass carp.
-
Q-VD-OPh: Reliable Caspase Inhibition
2026-09-18
Learn how Q-VD-OPh (SKU A1901) can clarify caspase-dependent cell death, support post-cryopreservation viability studies, and improve interpretation of apoptosis assays. This scenario-based guide covers experimental controls, solvent handling, data interpretation, and practical product selection.
-
AY 9944 Dihydrochloride: Causal DHCR7 Assays
2026-09-18
AY 9944 dihydrochloride is a selective DHCR7 inhibitor for experimentally shifting sterol balance from cholesterol toward 7-dehydrocholesterol. This article develops a causal assay framework that connects biochemical inhibition with immune, membrane-raft, and emerging antiviral evidence while distinguishing chemical perturbation from permanent gene disruption.
-
Dextromethorphan Hydrobromide for Neuroprotection
2026-09-17
Build more informative neuroprotection experiments with Dextromethorphan hydrobromide, an NMDA receptor antagonist tool that also affects voltage-operated ion currents. This guide connects concentration-response design, electrophysiology, excitotoxicity inhibition, and translational model selection while separating product facts from workflow starting points.
-
Ciprofloxacin–RSL3 Ferroptosis via STING1–CAV2
2026-09-17
The reference study shows that ciprofloxacin can either suppress or enhance ferroptosis depending on the initiating stimulus: it potentiates RSL3-induced death by driving mitochondrial Zn2+ accumulation through a STING1–CAV2 pathway. Its findings connect topoisomerase 2β inhibition, mitochondrial DNA stress, zinc transport, and mitochondrial reactive oxygen species, while also defining practical considerations for cell viability measurement in ferroptosis experiments.
-
Malate as a Flux and Redox Probe
2026-09-16
Malate and (S)-2-hydroxysuccinic acid provide a versatile way to interrogate TCA-cycle carbon flow, mitochondrial redox balance, and metabolic-immune signaling. This article translates recent cholangiocarcinoma findings into a practical assay framework that distinguishes flux effects from redox artifacts.
-
TG003: From Splicing Control to CLK2 Translation
2026-09-16
TG003 is a research-grade Cdc2-like kinase inhibitor that connects reversible control of serine/arginine-rich protein phosphorylation with translational questions in alternative splicing, exon-skipping therapy, and CLK2-associated platinum resistance.
-
AO/PI Cell Counting in Diabetic Nephropathy
2026-09-15
Learn how AO/PI Staining Solution and orthogonal viability measurements can strengthen mechanistic studies of diabetic nephropathy, including research on phillygenin, inflammation, and apoptosis.
-
L. reuteri FN041 Reshapes Colitis-Associated Microbiota
2026-09-15
This mouse study shows that human milk-derived Limosilactobacillus reuteri FN041 alleviates DSS-induced colitis alongside improvements in intestinal barrier markers, inflammatory responses, gut microbiota, and cecal metabolites. Its multi-omics design supports a microbiota–metabolite mechanism, while the findings remain preclinical and require validation in controlled translational studies.
-
NF 449: Designing Better P2X1 Platelet Assays
2026-09-14
NF 449 is a highly selective purinergic receptor antagonist for separating P2X1 signaling from broader platelet purinergic biology. This guide translates recombinant-receptor pharmacology into practical assay design, controls, storage decisions, and interpretation for platelet activation and thrombosis research.
-
U0126 for MEK1/2 Mechanistic Assays
2026-09-14
U0126 converts substrate-stiffness experiments from pathway correlation into testable MEK1/2 causality. This practical guide connects PDMS mechanobiology, time-resolved ERK readouts, mineralization assays, and troubleshooting for reproducible MAPK/ERK pathway inhibition.
-
Aβ42 Peptide: Ion Channels and Microglial Clearance
2026-09-13
A mechanistic guide to using human Amyloid β-Peptide (1-42) for integrated neurotoxicity, ion-channel, and microglial clearance studies in translational Alzheimer’s disease research.
-
HDAC Inhibitors Repress NUT Function in NUT Carcinoma
2026-09-12
Shiota and colleagues developed a dCAS9-based reporter screen that identified structurally diverse HDAC inhibitors as suppressors of NUT-driven transcription. The study connects HDAC inhibition with loss of BRD4-NUT megadomains, oncogene repression, cellular differentiation, and tumor-growth control, providing a mechanistic framework for therapeutic investigation in NUT carcinoma.
-
SCP4, H3T3 Dephosphorylation, and Chromosome Stability
2026-09-11
The reference study identifies SCP4 as a nuclear phosphatase that removes the mitotic H3T3 mark, refining the regulatory balance that positions the chromosomal passenger complex on mitotic chromosomes. Cellular and mouse-zygote experiments connect disrupted SCP4 activity with chromosome missegregation, aneuploidy, and early cleavage defects, establishing SCP4 as an important regulator of mitotic fidelity.